Adding balloon angioplasty to aggressive medical management significantly lowers the risk for stroke or death in patients with symptomatic intracranial atherosclerotic stenosis (sICAS), results of a ...

Novel drug-coated balloons (DCB) did not outshine standard treatment with second generation drug-eluting stents (DES) as they were expected to, in a surprise finding of the first randomized trial to ...

Old blood clots in lung arteries can obstruct blood flow and lead to pressure build-up in the affected arteries. When this happens, symptoms such as shortness of breath, fatigue, chest pain, and ...

First In-Man Experience Exceeds Expectations, Cited as “Game Changer” for Below-the-Knee Procedures CAMBRIDGE, Mass.--(BUSINESS WIRE)--Summa Therapeutics, LLC announced today that the first-in-man ...

Scripps Clinic interventional cardiologist Paul Teirstein, M.D., became the first in Southern California to use a newly approved drug-coated balloon to clear a clogged stent that previously had been ...

Submaximal balloon angioplasty for symptomatic intracranial atherosclerotic stenosis (ICAS) improved outcomes over aggressive medical management alone, the BASIS trial from China showed. The incidence ...

Results from the first randomized controlled trial to directly compare the safety and efficacy of cutting balloon (CB) angioplasty to intravascular lithotripsy (IVL) prior to drug-eluting stent (DES) ...

The US Food and Drug Administration (FDA) has approved Boston Scientific's Agent Drug-Coated Balloon (DCB), the first coronary DCB for the treatment of coronary in-stent restenosis in patients with ...